Palm Beach Neurological Center is participating in a global clinical research study to prevent or delay Alzheimer’s disease in cognitively healthy, older individuals that have been identified with one or two major genetic risk factors for the onset of Alzheimer’s disease.
The Generation Study 2 is a randomized, double-blind, placebo-controlled trial that tests whether the BACE inhibitor CNP520 can prevent or delay the symptoms of Alzheimer’s in people at a particularly higher risk due to their age. It also tests to determine if they carry one or two copies of the apolipoprotein E4 (APOE) gene, the major genetic risk factor for late-onset Alzheimer’s disease.
Qualifying participants will be randomly selected for one or two oral doses of the study medication, CNP520, in 15mg or 50mg dosages or a placebo. At the screening visit, a sample will be obtained by a check swab to determine if the subject carries the E 4 gene. If the results show this gene is present, the subject will be notified that they are eligible to participate in the Generation Study 2.
To qualify, participants must:
- Be cognitively healthy individuals between the ages of 60-75 years of age
- Must reside in the U.S.
- Carry one or two copies of the E4 type of the APOE gene
Why Join the Generation 2 Study?
- Receive an investigational drug designed to slow the onset of Alzheimer’s disease
- Receive the highest standard of study-related medical care
- All study-related medications and consultations during the study will be free of charge
- Help contribute to medical research